OnCo
drugsProductNot mapped hereapproved

Gallium-68 DOTATATE (and Cu-64 DOTATATE)

The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).

Ga-68 DOTATATE (Netspot, kit) approved June 2016; Cu-64 DOTATATE (Detectnet, 12.7-hour half-life allows central production) approved September 2020; Ga-68 DOTATOC (2019, academic). Changes management in about a third of patients; required before Lu-177 DOTATATE (Lutathera). Also images meningioma and paraganglioma.

Loading structure…
|
DOTATATE (oxodotreotide) · 2D coordinates (no PubChem conformer)
PubChem
How it works, step by step · animated schematic, not to scale
Radioligand therapy (beta emitters)
Modality
PET radiotracer (somatostatin receptor ligand)
Mechanism
Radiolabelled somatostatin analogue binding SSTR2 on neuroendocrine tumours; PET replaces the older In-111 octreotide SPECT with higher sensitivity and same-day imaging.
Brand / code
Netspot / Detectnet
Medicare
Part B (clinician-administered)

Diagnostic radiopharmaceutical billed with the PET/CT scan under Part B for neuroendocrine tumours (Netspot, Detectnet).

Commercial insurance
covered with prior authorisation

Covered for neuroendocrine tumour staging and Lutathera eligibility with prior authorisation of the PET scan.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.

Not appraisedSearch NICE
Appraised for
Somatostatin receptor PET for neuroendocrine tumours
Notes
Available at NHS PET centres and required before Lutathera (TA539). No TA.
NHS England
Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: gallium-68 DOTATATE PET. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

3top

Approvals

RegionYearIndication
US2016PET localisation of SSTR-positive neuroendocrine tumours (Ga-68 DOTATATE)
US2020Same (Cu-64 DOTATATE)
EU2017SomaKit TOC (Ga-68 DOTATOC)

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
14 studies4 recruiting14 Phase 2
Search “Gallium-68 DOTATATE” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Gallium-68 DOTATATE (and Cu-64 DOTATATE)
intervention: Gallium-68 DOTATATE
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Gallium-68 DOTATATE" OR ABSTRACT:"Gallium-68 DOTATATE" OR TITLE:"and Cu-64 DOTATATE" OR ABSTRACT:"and Cu-64 DOTATATE" OR TITLE:"Netspot" OR ABSTRACT:"Netspot" OR TITLE:"Detectnet" OR ABSTRACT:"Detectnet") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gallium-68 DOTATATE (and Cu-64 DOTATATE), not a curated reading list.

Connected

10top

Pages like this

not linked directly; found by shared links